All thresholds of maternal hyperglycaemia from the WHO 2013 criteria for gestational diabetes identify women with a higher genetic risk for type 2 diabetes [version 3; peer review: 2 approved, 1 approved with reservations]

Alice E. Hughes1,2, M. Geoffrey Hayes3, Aoife M. Egan4, Kashyap A. Patel1,2, Denise M. Scholtens3, Lynn P. Lowe3, William L. Lowe Jr1,2, Fidelma P. Dunne5, Andrew T. Hattersley1,2,6, Rachel M. Freathy1

1 Institute of Biomedical and Clinical Science, University of Exeter, Exeter, UK
2 Royal Devon and Exeter Hospitals NHS Foundation Trust, Exeter, UK
3 Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
4 Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic School of Medicine, Rochester, MN, USA
5 Galway Diabetes Research Centre and Saolta Hospital Group, National University of Ireland, Galway, Galway, Ireland
6 National Institute for Health Research Exeter Clinical Research Facility, Exeter, UK

Abstract

Background: Using genetic scores for fasting plasma glucose (FPG GS) and type 2 diabetes (T2D GS), we investigated whether the fasting, 1-hour and 2-hour glucose thresholds from the WHO 2013 criteria for gestational diabetes (GDM) have different implications for genetic susceptibility to raised fasting glucose and type 2 diabetes in women from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and Atlantic Diabetes in Pregnancy (DIP) studies.

Methods: Cases were divided into three subgroups: (i) FPG ≥5.1 mmol/L only, n=222; (ii) 1-hour glucose post 75 g oral glucose load ≥10 mmol/L only, n=154 (iii) 2-hour glucose ≥8.5 mmol/L only, n=172; and (iv) both FPG ≥5.1 mmol/L and either of a 1-hour glucose ≥10 mmol/L or 2-hour glucose ≥8.5 mmol/L, n=73. We compared the FPG and T2D GS of these groups with controls (n=3,091) in HAPO and DIP separately.

Results: In HAPO and DIP, the mean FPG GS in women with a FPG ≥5.1 mmol/L, either on its own or with 1-hour glucose ≥10 mmol/L or 2-hour glucose ≥8.5 mmol/L, was higher than controls (all P<0.01). Mean T2D GS in women with a raised FPG alone or with either a raised 1-hour or 2-hour glucose was higher than controls (all P<0.05). GDM defined by 1-hour or 2-hour hyperglycaemia only was also associated with a higher T2D GS than controls (all P<0.05).
Conclusions: The different diagnostic categories that are part of the WHO 2013 criteria for GDM identify women with a genetic predisposition to type 2 diabetes as well as a risk for adverse pregnancy outcomes.

Keywords
Gestational diabetes, genetic scores, fasting plasma glucose, type 2 diabetes

Corresponding author: Rachel M. Freathy (r.freathy@exeter.ac.uk)

Author roles: Hughes AE: Formal Analysis, Investigation, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Hayes MG: Data Curation, Formal Analysis, Writing – Review & Editing; Egan AM: Data Curation, Writing – Review & Editing; Patel KA: Formal Analysis, Writing – Review & Editing; Scholtens DM: Data Curation, Formal Analysis, Writing – Review & Editing; Lowe LP: Data Curation, Writing – Review & Editing; Lowe Jr WL: Conceptualization, Data Curation, Methodology, Supervision, Writing – Review & Editing; Dunne FP: Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Writing – Review & Editing; Hattersley AT: Conceptualization, Formal Analysis, Methodology, Supervision, Writing – Review & Editing; Freathy RM: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by Wellcome [GW4 Clinical Academic Training PhD Fellowship to AEH; 110082, Postdoctoral Training Fellowship to KAP; 104150, a Wellcome and Royal Society Sir Henry Dale Fellowship to RMF; 088541, a Sir Henry Wellcome Postdoctoral Fellowship to RMF was used to fund genotyping of the SNPs in HAPO and DIP]. AEH was also funded by the National Institute of Health Research (NIHR). ATH is a Wellcome Trust Senior Investigator (098395) and NIHR senior investigator. HAPO was supported by grants from Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD-34242 and HD-32423), National Human Genome Research Institute (HG-004415), the National Institute of Diabetes and Digestive and Kidney Diseases (DK-DK097534) and the American Diabetes Association. DIP was supported by grants from the Ireland Health Research Board. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Hughes AE et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Hughes AE, Hayes MG, Egan AM et al. All thresholds of maternal hyperglycaemia from the WHO 2013 criteria for gestational diabetes identify women with a higher genetic risk for type 2 diabetes [version 3; peer review: 2 approved, 1 approved with reservations] Wellcome Open Research 2021, 5:175 https://doi.org/10.12688/wellcomeopenres.16097.3

First published: 22 Jul 2020, 5:175 https://doi.org/10.12688/wellcomeopenres.16097.1
Introduction

Gestational diabetes mellitus (GDM) has been variably defined since criteria were first developed over 50 years ago\(^1\). The World Health Organization (WHO) introduced diagnostic criteria for GDM in 1999, based on criteria for overt diabetes in the general population, with a fasting plasma glucose (FPG) ≥7.0 mmol/L or impaired glucose tolerance with a 2-hour glucose ≥7.8 mmol/L post 75 g oral glucose load as part of an oral glucose tolerance test (OGTT), measured between 24 and 28 weeks gestation\(^2\). However, lesser degrees of maternal fasting hyperglycaemia have long been associated with a higher risk for adverse perinatal outcomes\(^3\), so a FPG ≥6.1 mmol/L (indicative of impaired fasting glycaemia in the non-pregnant population\(^4\)) was also integrated into the WHO criteria.

The Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study\(^5\) followed 23,316 women who underwent a 2-hour OGTT between 24 and 32 weeks gestation throughout pregnancy and found a continuous association between maternal glucose values and adverse perinatal outcomes, including birth weight ≥90\(^{th}\) centile (large for gestational age, LGA) and primary caesarean section. In 2010, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) determined cut-off values equivalent to 1.75 times the odds for adverse pregnancy outcomes at mean glucose values, resulting in diagnostic thresholds for FPG ≥5.1 mmol/L, 1-hour glucose ≥10 mmol/L and 2-hour glucose ≥8.5 mmol/L\(^5\).

WHO adopted the recommendations of IADPSG in 2013\(^3\), which has resulted in a higher number of cases identified as GDM due to the lower FPG threshold (estimated up to 17.8% prevalence of GDM for IADPSG 2010 criteria\(^6\) vs 9.4% prevalence for WHO 1999 criteria\(^1\)). Whilst these thresholds were chosen for their Obstetric risks, the HAPO Follow-Up Study found that women diagnosed by the newer criteria have a higher risk of developing disorders of glucose metabolism, including T2D, 10 years after the episode of GDM\(^6\). A proportion of this risk can be attributed to genetic predisposition, since genome wide association study (GWAS) data from large, non-pregnant population-based studies have identified multiple loci associated with FPG\(^7\) and type 2 diabetes\(^8\) and some of these are shared with GDM\(^11\)–\(^16\). Specific to the WHO 2013 criteria, single nucleotide polymorphisms (SNPs) at the GCK and TCF7L2 loci were shown to be associated with FPG and 2-hour glucose levels post-OGTT in women with GDM\(^17\). In addition, genetic risk scores for glycaemic traits, including FPG and type 2 diabetes, have been associated with a higher odds for GDM according to the WHO 2013 criteria\(^18\). However, it is not known whether the underlying genetic predisposition to fasting hyperglycaemia and type 2 diabetes varies depending on how the diagnosis of GDM is met.

The objective of this study was to investigate whether there is a difference in genetic risk for fasting hyperglycaemia and type 2 diabetes according to the different diagnostic thresholds of glucose tolerance from the WHO 2013 criteria for GDM. To do this, we used a genetic score (GS) for FPG (FPG GS) or T2D (T2D GS) (consisting of previously-identified loci\(^7\)–\(^9\))

Methods

Study population

Women of European ancestry (self-reported white ethnicity) with singleton pregnancies and without known pre-existing diabetes from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study\(^5\) (n=2,628) and Atlantic Diabetes in Pregnancy (DIP) study\(^20\) (n=1,084) were included. The HAPO study was an observational, multi-centre study (N=23,316 participants from 15 centres) to which women were recruited during pregnancy if they were over 18 years of age\(^1\). The 2,665 European-ancestry participants included in the current study were those with genotype data available on selected SNPs (see below). The DIP study had a case-control design: approximately three genotyped control participants without GDM (defined initially as a maternal FPG <5.6 mmol/L and/or 2-hour glucose post oral glucose load <7.8 mmol/L) were available for every genotyped case participant included in our analyses.

Sample collection and clinical characteristics

The study methods used in HAPO and DIP have been described in detail previously\(^13\)–\(^22\). Maternal FPG in mmol/L was measured prior to a standard 2-hour OGTT with 75 g of glucose between 24 and 32 weeks in HAPO and 24 and 28 weeks in DIP. Information on maternal age, pre-pregnancy body mass index (BMI) and systolic blood pressure (SBP, in mmHg) was collected at the OGTT appointment. Clinical characteristics of participants in HAPO and DIP with and without GDM were different (women in DIP were older, had a higher BMI and higher SBP, all P <0.01), hence clinical characteristics (where available) have been presented separately.

GDM diagnostic criteria subgroups

We used the WHO 2013 cut-offs (previously IADPSG 2010) to define fasting and 2-hour hyperglycaemia. Thus, in the
current study, women diagnosed with GDM were divided into fasting hyperglycaemia only (FPG $\geq 5.1$ mmol/L and 1-hour and 2-hour glucose post 75 g oral glucose load <10 mmol/L and <8.5 mmol/L, respectively, n=222), elevated 1-hour glucose only (1-hour glucose $\geq 10$ mmol/L, FPG <5.1 mmol/L and 2-hour glucose <8.5 mmol/L, n=154), elevated 2-hour glucose only (2-hour glucose $\geq 8.5$ mmol/L, FPG <5.1 mmol/L and 1-hour glucose <10 mmol/L, n=73) and both (FPG $\geq 5.1$ mmol/L and either a 1-hour glucose $\geq 10$ mmol/L or 2-hour glucose $\geq 8.5$ mmol/L, or both, n=172) subgroups Figure 1. Women without GDM were defined as having FPG <5.1 mmol/L, 1-hour glucose <10 mmol/L and 2-hour glucose <7.8 mmol/L (n=3,091). The distributions of the women in the different groups and in each of the study cohorts are shown in Figure 1.

Genotyping

Genotyping of individual SNPs in DNA samples from both the DIP and HAPO studies was carried out at LGC Genomics (Hoddesdon, UK), using the PCR-based KASP$^{TM}$ genotyping assay. We first selected 41 SNPs that had been previously associated with type 2 diabetes, and 16 SNPs associated with fasting glucose in non-pregnant individuals, for genotyping in the DIP study. Overlap between the type 2 diabetes and FPG SNPs meant that seven FPG loci were also in the list of type 2 diabetes loci. The median genotyping call rate in the DIP samples was 0.992 (range 0.981–0.996), and there was >99% concordance between duplicate samples (8% of total genotyped samples were duplicates). We excluded one FPG SNP and one type 2 diabetes SNP that showed deviation from Hardy-Weinberg Equilibrium (Bonferroni-corrected P value <0.05). For details of included and excluded SNPs and their sources, see Table 1 and Table 2.

In the HAPO study, we selected SNPs from the same 16 FPG and 41 type 2 diabetes loci for genotyping in women of European ancestry with DNA available. The selection and genotyping of SNPs in the HAPO study was performed at different times from that in the DIP study. Owing to the differing availability of published GWAS results at these times, the genotyped SNPs differed between HAPO and DIP at 9 of the associated loci. The HAPO SNPs at the nine loci were generally well correlated with those genotyped in DIP ($r^2 >0.7$, apart from at the ADAMTS9 locus where $r^2 = 0.45$). The median genotyping call rate in the HAPO samples was 0.984 (range 0.955–0.991), and the mean concordance between duplicate samples was >98.5% (at least 1% of samples were duplicated). We excluded one SNP that showed deviation from Hardy-Weinberg Equilibrium in the HAPO study (Bonferroni-corrected P value <0.05; see Table 1 and Table 2). After exclusion of SNPs that showed deviation from Hardy-Weinberg equilibrium and one SNP from the type 2 diabetes score whose main effect was on BMI (rs11642841 (FTO locus)$^{23}$, a total of 15 SNPs at FPG-associated loci and 38 SNPs at type 2 diabetes-associated loci were available in both studies for analysis.

Figure 1. Distribution of participants diagnosed with gestational diabetes (GDM) by different glucose categories in Hyperglycemia and Adverse Pregnancy Outcome Study (HAPO) and Atlantic Diabetes in Pregnancy Study (DIP). All glucose values are in mmol/L. The 1-hour and 2-hour glucose measures refer to the glucose level measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test. Women with a FPG $\geq 5.1$ mmol/L and either a 1-hour glucose $\geq 10$ mmol/L or 2-hour glucose $\geq 8.5$ mmol/L, or both, were combined as one group for analyses.
Table 1. Fifteen SNPs associated with fasting plasma glucose (FPG) and used to construct the FPG genetic score.

<table>
<thead>
<tr>
<th>Chr:Pos (hg19)</th>
<th>SNP (proxy)</th>
<th>Locus</th>
<th>Effect/Other Alleles (Proxy)</th>
<th>Effect Allele Frequency (Proxy)</th>
<th>Beta (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:214159256</td>
<td>rs340874</td>
<td>PROX1</td>
<td>C/T</td>
<td>0.57</td>
<td>0.013</td>
</tr>
<tr>
<td>2:27741237</td>
<td>rs780094</td>
<td>GCKR</td>
<td>C/T</td>
<td>0.62</td>
<td>0.029</td>
</tr>
<tr>
<td>2:169763148</td>
<td>rs560887</td>
<td>G6PC2</td>
<td>C/T</td>
<td>0.70</td>
<td>0.075</td>
</tr>
<tr>
<td>3:123065778</td>
<td>rs11708067</td>
<td>ADCYS</td>
<td>A/G (C/T)</td>
<td>0.75 (0.73)</td>
<td>0.027</td>
</tr>
<tr>
<td>3:170717521</td>
<td>rs11920090</td>
<td>SLC2A2</td>
<td>T/A</td>
<td>0.88</td>
<td>0.020</td>
</tr>
<tr>
<td>7:15064309</td>
<td>rs2191349</td>
<td>DGKB/TMEM195</td>
<td>T/G</td>
<td>0.55</td>
<td>0.030</td>
</tr>
<tr>
<td>7:44235668</td>
<td>rs4607517</td>
<td>GCK</td>
<td>A/G (T/C)</td>
<td>0.18 (0.18)</td>
<td>0.062</td>
</tr>
<tr>
<td>8:118184783</td>
<td>rs13266634</td>
<td>SLC30A8</td>
<td>C/T</td>
<td>0.69</td>
<td>0.027</td>
</tr>
<tr>
<td>9:4289050</td>
<td>rs7034200</td>
<td>GLIS3</td>
<td>A/C</td>
<td>0.48</td>
<td>0.018</td>
</tr>
<tr>
<td>10:114758349</td>
<td>rs7903146</td>
<td>TCF7L2</td>
<td>T/C</td>
<td>0.29</td>
<td>0.023</td>
</tr>
<tr>
<td>11:45873091</td>
<td>rs11605924</td>
<td>CRY2</td>
<td>A/C</td>
<td>0.48</td>
<td>0.015</td>
</tr>
<tr>
<td>11:47336320</td>
<td>rs7944584</td>
<td>MADD</td>
<td>A/T</td>
<td>0.72</td>
<td>0.021</td>
</tr>
<tr>
<td>11:61571478</td>
<td>rs174550</td>
<td>FAOS1</td>
<td>T/C</td>
<td>0.65</td>
<td>0.017</td>
</tr>
<tr>
<td>11:92708710</td>
<td>rs10830963</td>
<td>MTNR1B</td>
<td>G/C</td>
<td>0.28</td>
<td>0.067</td>
</tr>
<tr>
<td>15:62433962</td>
<td>rs11071657</td>
<td>C2CD4B</td>
<td>A/G</td>
<td>0.62</td>
<td>0.008</td>
</tr>
</tbody>
</table>

SNP, single nucleotide polymorphism. Proxy SNPs were genotyped and analysed in the Hyperglycemia and Adverse Pregnancy Outcome Study (both rs2 > 0.85 in 340,000 British white unrelated samples from Version 3 release of UK Biobank, calculated using PLINK software). Effect allele frequency was calculated in 340,000 British white unrelated samples from the UK Biobank. Beta values were aligned to the trait-raising allele on the + strand (Human Genome Assembly Reference hg19). Source of SNPs and beta values: Dupuis et al., 2010.9 We used the same Beta values for proxy SNPs. We excluded rs10885122 (ADRA2A locus) due to deviation from Hardy-Weinberg Equilibrium in the Atlantic Diabetes In Pregnancy Study (Bonferroni corrected P < 0.05).

Generating a genetic score for FPG and type 2 diabetes
Weighted genetic scores for FPG (FPG GS) and type 2 diabetes (T2D GS) were generated using the 15 SNPs and 38 SNPs, respectively. All weights for the FPG GS and T2D GS were taken from Dupuis et al.9 and Voight et al.26, respectively. The GSs were calculated by taking the sum of the number of FPG-raising or type 2 diabetes risk alleles (0, 1 or 2) for each SNP, multiplied by its corresponding beta value (effect size, see Table 1 and Table 2) for association with FPG or type 2 diabetes, divided by the sum of all beta values and multiplied by the total number of SNPs analysed (see Figure 2 for formula). GS were generated for participants with complete data for all included SNPs only.

Statistical analyses
Analysis of clinical characteristics. Clinical characteristics were compared between participants with and without GDM in HAPO and DIP using unpaired t-tests for normally distributed data and the Wilcoxon Rank-Sum test for non-normally distributed data. P values were corrected for 24 comparisons using the Bonferroni method.

Analysis of associations between FPG GS or T2D GS with glucose levels and GDM. Associations of the FPG GS or T2D GS with FPG, 1-hour and 2-hour glucose in women with and without GDM (cases and controls) were analysed using linear regression in HAPO (which was a representative sample of European participants from the whole study cohort) and DIP. P values were corrected for 24 comparisons using the Bonferroni method. Our sample of N=2,628 HAPO and N=1,084 DIP participants both provided 100% power to detect associations between fasting glucose levels and the fasting glucose GS at α=0.002, assuming the GS explains 6% variance in glucose levels, which was estimated in 849 pregnant
Table 2. Thirty-eight SNPs associated with type 2 diabetes (T2D) risk and used to construct the T2D genetic score.

<table>
<thead>
<tr>
<th>Chr:Pos (hg19)</th>
<th>SNP (proxy)*</th>
<th>Locus</th>
<th>Effect/Other Alleles (Proxy)</th>
<th>Effect Allele Frequency (Proxy)b</th>
<th>Betac</th>
<th>Source in which SNP was originally identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:120526982</td>
<td>rs1493694</td>
<td>NOTCH2</td>
<td>T/C</td>
<td>0.11</td>
<td>0.110</td>
<td>Zeggini et al., 2008 [27]</td>
</tr>
<tr>
<td>1:214163675</td>
<td>rs340835</td>
<td>PROX1</td>
<td>A/G</td>
<td>0.49</td>
<td>0.062</td>
<td>Dupuis et al., 2010 [9]</td>
</tr>
<tr>
<td>2:27741237</td>
<td>rs780994</td>
<td>GCKR</td>
<td>C/T</td>
<td>0.62</td>
<td>0.011</td>
<td>Dupuis et al., 2010 [9]</td>
</tr>
<tr>
<td>2:43732823</td>
<td>rs7578597</td>
<td>THADA</td>
<td>T/C</td>
<td>0.89</td>
<td>0.141</td>
<td>Zeggini et al., 2008 [27]</td>
</tr>
<tr>
<td>2:60584191</td>
<td>rs243021</td>
<td>BCL11A</td>
<td>A/G</td>
<td>0.46</td>
<td>0.090</td>
<td>Voight et al., 2010 [58]</td>
</tr>
<tr>
<td>2:227093745</td>
<td>rs2943641</td>
<td>IRS1</td>
<td>C/T</td>
<td>0.65 (0.65)</td>
<td>0.083</td>
<td>Zeggini et al., 2008 [27]</td>
</tr>
<tr>
<td>3:12393125</td>
<td>rs1801282</td>
<td>PPARG</td>
<td>C/G</td>
<td>0.88</td>
<td>0.138</td>
<td>Altshuler et al., 2000 [29]</td>
</tr>
<tr>
<td>3:23336450</td>
<td>rs7612463</td>
<td>UBE2E2</td>
<td>C/A</td>
<td>0.89</td>
<td>0.102</td>
<td>Yamauchi et al., 2010 [30]</td>
</tr>
<tr>
<td>3:64711904</td>
<td>rs4607103</td>
<td>ADAMTS9</td>
<td>C/T</td>
<td>0.76 (0.59)</td>
<td>0.092</td>
<td>Dupuis et al., 2010 [9]</td>
</tr>
<tr>
<td>3:123065778</td>
<td>rs11708067</td>
<td>ADCY5</td>
<td>A/G</td>
<td>0.75 (0.73)</td>
<td>0.097</td>
<td>Zeggini et al., 2008 [27]</td>
</tr>
<tr>
<td>4:6292915</td>
<td>rs10010131</td>
<td>WFS1</td>
<td>G/A</td>
<td>0.60</td>
<td>0.104</td>
<td>Sandhu et al., 2007 [31]</td>
</tr>
<tr>
<td>5:76424949</td>
<td>rs4457053</td>
<td>ZBED3</td>
<td>G/A</td>
<td>0.32</td>
<td>0.150</td>
<td>Voight et al., 2010 [26]</td>
</tr>
<tr>
<td>6:20661250</td>
<td>rs7754840</td>
<td>CDKAL1</td>
<td>C/G (C/T)</td>
<td>0.31 (0.26)</td>
<td>0.170</td>
<td>Zeggini et al., 2007 [27]</td>
</tr>
<tr>
<td>7:28189411</td>
<td>rs1635852</td>
<td>JAZF1</td>
<td>T/C</td>
<td>0.49</td>
<td>0.120</td>
<td>Zeggini et al., 2008 [27]</td>
</tr>
<tr>
<td>7:44235668</td>
<td>rs4607517</td>
<td>GCK</td>
<td>A/G (C/T)</td>
<td>0.18 (0.18)</td>
<td>0.029</td>
<td>Dupuis et al., 2010 [9]</td>
</tr>
<tr>
<td>7:130466854</td>
<td>rs972283</td>
<td>KLF14</td>
<td>G/A (C/T)</td>
<td>0.51 (0.51)</td>
<td>0.099</td>
<td>Kong et al., 2009 [13]</td>
</tr>
<tr>
<td>8:95937502</td>
<td>rs7845219</td>
<td>TPS3INP1</td>
<td>T/C</td>
<td>0.50</td>
<td>0.093</td>
<td>Voight et al., 2010 [26]</td>
</tr>
<tr>
<td>8:118184783</td>
<td>rs13266634</td>
<td>SLC30A8</td>
<td>C/T</td>
<td>0.69</td>
<td>0.139</td>
<td>Sladek et al., 2007 [24]</td>
</tr>
<tr>
<td>9:22133284</td>
<td>rs10965250</td>
<td>CDKN2A/B</td>
<td>G/A</td>
<td>0.83</td>
<td>0.181</td>
<td>Zeggini et al., 2007 [27]</td>
</tr>
<tr>
<td>9:81952128</td>
<td>rs13292136</td>
<td>CHCHD9</td>
<td>C/T</td>
<td>0.93</td>
<td>0.182</td>
<td>Voight et al., 2010 [26]</td>
</tr>
<tr>
<td>10:12328010</td>
<td>rs12779790</td>
<td>CDC123'/CAMK1D</td>
<td>G/A (T/C)</td>
<td>0.18 (0.21)</td>
<td>0.088</td>
<td>Zeggini et al., 2008 [27]</td>
</tr>
<tr>
<td>10:94465559</td>
<td>rs5015480</td>
<td>HHEX/IDE</td>
<td>C/T</td>
<td>0.59</td>
<td>0.166</td>
<td>Zeggini et al., 2007 [27]</td>
</tr>
<tr>
<td>10:114758349</td>
<td>rs7903146</td>
<td>TCF7L2</td>
<td>T/C</td>
<td>0.29</td>
<td>0.335</td>
<td>Grant et al., 2006 [45]</td>
</tr>
<tr>
<td>11:1696849</td>
<td>rs2334499</td>
<td>HCCA2/ DUSP8</td>
<td>T/C</td>
<td>0.42</td>
<td>0.080</td>
<td>Kong et al., 2009 [13]</td>
</tr>
<tr>
<td>11:2691471</td>
<td>rs231362</td>
<td>KCNQ1</td>
<td>G/A</td>
<td>0.52</td>
<td>0.104</td>
<td>Kong et al., 2009 [13]</td>
</tr>
<tr>
<td>11:2847069</td>
<td>rs163184</td>
<td>KCNQ1</td>
<td>G/T</td>
<td>0.48</td>
<td>0.083</td>
<td>Yasuda et al., 2008 [16], Unoki et al., 2008 [32]</td>
</tr>
<tr>
<td>11:17408630</td>
<td>rs5215</td>
<td>KCNJ11</td>
<td>C/T</td>
<td>0.36</td>
<td>0.089</td>
<td>Gloyn et al., 2003 [28]</td>
</tr>
<tr>
<td>11:72433098</td>
<td>rs1552224</td>
<td>CENDT2</td>
<td>A/C</td>
<td>0.84</td>
<td>0.123</td>
<td>Voight et al., 2010 [26]</td>
</tr>
<tr>
<td>11:92673828</td>
<td>rs1387153</td>
<td>MTNR1B</td>
<td>T/C (G/C)</td>
<td>0.29 (0.28)</td>
<td>0.115</td>
<td>Prokopenko et al., 2009 [50], Dupuis et al., 2010 [9]</td>
</tr>
<tr>
<td>Chr:Pos (hg19)</td>
<td>SNP (proxy)</td>
<td>Locus</td>
<td>Effect/Other Alleles (Proxy)</td>
<td>Effect Allele Frequency (Proxy)</td>
<td>Beta</td>
<td>Source in which SNP was originally identified</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>-------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>12:66170163</td>
<td>rs2612067</td>
<td>HMG2</td>
<td>G/T</td>
<td>0.10</td>
<td>0.180</td>
<td>Voight et al., 2010</td>
</tr>
<tr>
<td>12:71613276</td>
<td>rs1353362</td>
<td>TSPAN8/LGR5</td>
<td>C/T</td>
<td>0.28</td>
<td>0.103</td>
<td>Zeggini et al., 2008</td>
</tr>
<tr>
<td>12:121402932</td>
<td>rs7305618</td>
<td>HNF1A</td>
<td>C/T (G/C)</td>
<td>0.77 (0.81)</td>
<td>0.112</td>
<td>Voight et al., 2010</td>
</tr>
<tr>
<td>13:80717156</td>
<td>rs1359790</td>
<td>SPRY2</td>
<td>G/A</td>
<td>0.71</td>
<td>0.096</td>
<td>Shu et al., 2010</td>
</tr>
<tr>
<td>15:62396389</td>
<td>rs7172432</td>
<td>C2CD4A/B</td>
<td>A/G</td>
<td>0.57</td>
<td>0.068</td>
<td>Yamauchi et al., 2010</td>
</tr>
<tr>
<td>15:7774190</td>
<td>rs7178572</td>
<td>HMG2A</td>
<td>G/A</td>
<td>0.71</td>
<td>0.068</td>
<td>Kooner et al., 2011</td>
</tr>
<tr>
<td>15:80432222</td>
<td>rs11634397</td>
<td>ZFAND6</td>
<td>G/A</td>
<td>0.66</td>
<td>0.102</td>
<td>Voight et al., 2010</td>
</tr>
<tr>
<td>17:36098040</td>
<td>rs4430796</td>
<td>HNF1B</td>
<td>G/A</td>
<td>0.48</td>
<td>0.130</td>
<td>Gudmundsson et al., 2007</td>
</tr>
<tr>
<td>X:152908152</td>
<td>rs2301142</td>
<td>DUSP9</td>
<td>A/G</td>
<td>0.85</td>
<td>0.086</td>
<td>Voight et al., 2010</td>
</tr>
</tbody>
</table>

SNP: single nucleotide polymorphism. Proxy SNPs were genotyped and analysed in the Hyperglycemia and Adverse Pregnancy Outcome Study (r² > 0.7 in 340,000 British white unrelated samples from Version 3 release of UK Biobank, except for at ADAMTS9 where r² = 0.45 (calculated using PLINK software)). Effect allele frequency was calculated in 340,000 British white unrelated samples from the UK Biobank. Beta values were aligned to the T2D-risk allele on the + strand (Human Genome Assembly Reference hg19). Beta value = log odds ratio for T2D from genome-wide association study meta-analysis of up to 8130 cases and 38987 controls, published in Voight et al., 2010. We used the same Beta value for proxy SNPs. We excluded rs8042680 (PRC1 locus, Atlantic Diabetes in Pregnancy Study) and rs1470579 (IGF2BP2 locus, Hyperglycemia and Adverse Pregnancy Outcome Study) from the T2D GS due to deviation from Hardy-Weinberg Equilibrium (Bonferroni-corrected P < 0.05). We additionally excluded rs11642841 (FTO locus) due to its primary effect on BMI.

**Figure 2. Formula for generating a weighted genetic score (GS).** “Number of alleles” corresponds to either the number of risk alleles (type 2 diabetes single-nucleotide polymorphisms (SNPs)) or the number of glucose-raising alleles (fasting plasma glucose SNPs).

$$\text{Weighted GS} = \left( \frac{\text{sum (number of alleles for each SNP x Beta)}}{\text{sum of Beta values}} \right) \times \text{total number of SNPs}$$

individuals without diabetes in an external study (Exeter Family Study of Childhood Health (EFSOCH)). Means for FPG GS and T2D GS in women with and without GDM were compared using unpaired t-tests in each study cohort separately, as the genetic scores were higher overall in DIP. P values were Bonferroni corrected for 16 comparisons. Sensitivity analyses adjusting GS for maternal pre-pregnancy BMI and age (where available) were performed using ANCOVA.

**Statistical software.** All statistical analyses were performed using Stata version 14.0 (StataCorp LP, College Station, TX, USA). P-values <0.05 were considered to indicate evidence of association, unless otherwise stated.

**Ethics approval.** Ethics approval was obtained from the Northwestern University Office for the Protection of Research Participants for HAPO (Protocol # 0353-001). The HAPO study protocol was approved by the institutional review board at each field center and all participants gave written, informed consent. Ethics approval was obtained from the local Galway University Hospital Research Ethics Committee for Atlantic DIP (Ref: 54/05) and all participants gave written, informed consent.

**Results**

Clinical characteristics in women with and without GDM

Clinical characteristics for women with and without GDM are summarised in Table 3 for HAPO and DIP, respectively. Women with a FPG ≥5.1 mmol/L (on its own or with either 1-hour or 2-hour hyperglycaemia) had a higher pre-pregnancy BMI than women without GDM in HAPO and DIP (P values <0.001). Women with both fasting and either 1-hour or 2-hour hyperglycaemia were older compared with controls in HAPO (P value <0.05 after Bonferroni correction). In HAPO we observed a higher SBP for women diagnosed with GDM by a FPG ≥5.1 mmol/L only compared with controls (P value <0.001) and they had a higher SBP when either their 1-hour or 2-hour glucose was also raised, but the P value was >0.05 after Bonferroni correction. In DIP there was a higher SBP for women diagnosed by both fasting and either 1-hour or 2-hour hyperglycaemia criteria compared with controls (P value <0.05 after Bonferroni correction).
Table 3. Clinical characteristics for participants diagnosed with gestational diabetes (GDM) by the different criteria in the Hyperglycemia and Adverse Pregnancy Outcome Study (A) and the Atlantic Diabetes in Pregnancy Study (B).

**A) HAPO**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Controls with normal glucose</th>
<th>FPG ≥5.1 mmol/L only</th>
<th>1-hr glucose≥10 mmol/L only</th>
<th>2-hr glucose≥8.5 mmol/L only</th>
<th>Both (FPG ≥5.1 mmol/L and either 1-hr glucose≥10 mmol/L or 2-hr glucose≥8.5 mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median FPG in mmol/L (IQR)</td>
<td>4.5 (4.3-4.7) n=2,275</td>
<td>5.2 (5.1-5.3) n=164</td>
<td>4.8 (4.6-4.9) n=66</td>
<td>4.5 (4.3-4.7) n=48</td>
<td>5.3 (5.2-5.5) n=75</td>
</tr>
<tr>
<td>Median 1-hr glucose in mmol/L (IQR)</td>
<td>7.1 (6.0-8.0) n=2,275</td>
<td>8.4 (7.6-9.2) n=164</td>
<td>10.4 (10.2-11.0) n=66</td>
<td>9.0 (8.6-9.5) n=48</td>
<td>10.6 (10.0-11.2) n=75</td>
</tr>
<tr>
<td>Median 2-hr glucose in mmol/L (IQR)</td>
<td>5.8 (5.1-6.5) n=2,275</td>
<td>6.6 (6.0-7.1) n=164</td>
<td>7.4 (6.6-7.9) n=66</td>
<td>8.9 (8.6-9.1) n=48</td>
<td>7.9 (7.1-8.9) n=75</td>
</tr>
<tr>
<td>Median maternal age in years (IQR)</td>
<td>31 (26-34) n=2,275</td>
<td>31 (27-35) n=164</td>
<td>31 (27-35) n=66</td>
<td>32 (27-34) n=48</td>
<td>32 (29-36)** n=75</td>
</tr>
<tr>
<td>Median prepregnancy BMI (IQR)</td>
<td>22.9 (21.0-26.1) n=2,125</td>
<td>27.5 (23.8-33.1)** n=164</td>
<td>24.4 (21.2-27.9) n=59</td>
<td>23.0 (20.1-25.1) n=45</td>
<td>28.0 (23.8-35.2)** n=65</td>
</tr>
<tr>
<td>Median SBP in mmHg (IQR)</td>
<td>108 (102-114) n=2,275</td>
<td>113 (106-119)***(IQR) n=164</td>
<td>110 (103-118) n=66</td>
<td>104 (100-116) n=48</td>
<td>110 (103-118)** n=75</td>
</tr>
<tr>
<td>Mean FPG GS (SD)</td>
<td>15.50 (2.93) n=2,275</td>
<td>16.99 (2.90)***(IQR) n=164</td>
<td>16.51 (2.88)** n=66</td>
<td>16.11 (2.06) n=48</td>
<td>16.84 (2.72)** n=75</td>
</tr>
<tr>
<td>Mean T2D GS (SD)</td>
<td>41.19 (4.03) n=2,275</td>
<td>42.05 (3.90)***(IQR) n=164</td>
<td>42.18 (4.15)** n=66</td>
<td>43.40 (4.41)** n=48</td>
<td>42.74 (5.07)** n=75</td>
</tr>
</tbody>
</table>

**B) DIP**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Controls with normal glucose</th>
<th>FPG ≥5.1 mmol/L only</th>
<th>1-hr glucose≥10 mmol/L only</th>
<th>2-hr glucose≥8.5 mmol/L only</th>
<th>Both (FPG ≥5.1 mmol/L and either 1-hr glucose≥10 mmol/L or 2-hr glucose≥8.5 mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median FPG in mmol/L (IQR)</td>
<td>4.3 (4.1-4.5) n=816</td>
<td>5.3 (5.2-5.5) n=58</td>
<td>4.6 (4.4-4.8) n=88</td>
<td>4.5 (4.2-4.7) n=25</td>
<td>5.5 (5.2-5.9) n=97</td>
</tr>
<tr>
<td>Median 1-hr glucose in mmol/L (IQR)</td>
<td>6.6 (5.6-7.7) n=816</td>
<td>8.7 (7.5-9.1) n=58</td>
<td>10.8 (10.2-11.2) n=88</td>
<td>8.6 (8.1-9.1) n=25</td>
<td>11.2 (10.2-12.0) n=97</td>
</tr>
<tr>
<td>Median 2-hr glucose in mmol/L (IQR)</td>
<td>5.2 (4.6-6.0) n=816</td>
<td>6.1 (5.5-7.0) n=58</td>
<td>6.9 (5.9-7.8) n=88</td>
<td>8.8 (8.6-9.2) n=25</td>
<td>8.5 (7.5-9.3) n=97</td>
</tr>
<tr>
<td>Median maternal age in years (IQR)</td>
<td>32 (29-36) n=521</td>
<td>35 (31-39)* n=35</td>
<td>34 (31-37)* n=69</td>
<td>32 (29-40) n=16</td>
<td>33 (30-36) n=72</td>
</tr>
</tbody>
</table>
FPG, 1-hour and 2-hour glucose are associated with FPG and T2D GS in pregnant women with and without GDM

FPG, 1-hour and 2-hour glucose values were associated with the fasting and type 2 diabetes genetic scores in HAPO and DIP Table 4. Adjusting for the different measures of glucose tolerance suggested that these associations were not independent of one another.

Women diagnosed with GDM by fasting glucose criteria have a higher FPG GS

We observed a higher FPG GS in women diagnosed with GDM by fasting hyperglycaemia only and by both fasting and either 1-hour or 2-hour criteria, compared with controls (Figure 3A, all P values for comparison with control group <0.05 after Bonferroni correction). There was also evidence that women with a raised 1-hour glucose only had a higher FPG GS in HAPO (P value for comparison with controls <0.01 but >0.05 with Bonferroni correction), but this was not as strong in DIP (P value =0.05). In contrast, women diagnosed with GDM by 2-hour only criteria did not have a higher FPG GS overall (P values for comparison with controls >0.05 in both studies). Sensitivity analyses adjusted for maternal BMI and age did not materially alter the GS relationships (Extended data Tables 1A and 1B).

Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria have a higher T2D GS than controls

The T2D GS was higher than controls in women with fasting, 1-hour or 2-hour hyperglycaemia in HAPO and DIP (Figure 3B): all P values for comparison with controls were <0.05 after correction except for the fasting and 1-hour only groups. As with the FPG GS, sensitivity analyses adjusted for maternal BMI and age did not materially affect the associations seen (Extended data Tables 1A and 1B).

**Discussion and conclusions**

In this study of 3,712 pregnant women of European ancestry, we have confirmed that women diagnosed with GDM according to the WHO 2013 criteria have a raised genetic risk for type 2 diabetes and shown for the first time that this risk was raised across all of the different measures of glucose tolerance. A genetic predisposition to a higher FPG was present for women who met the fasting glucose criteria (and 1-hour glucose criteria in HAPO), but was not present for women who met the 2-hour criteria.

We confirmed that FPG in pregnant women both with and without GDM was positively associated with a FPG GS generated using SNPs identified in a non-pregnant population\(^6\). The 1-hour and 2-hour glucose values were also correlated with the FPG GS, but this could potentially be explained by their association with FPG, since this association was not as strong once this was taken into account. Thus, the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥8.5 mmol/L alone was likely because these women did not have fasting hyperglycemia. However, larger sample sizes would be needed to confidently rule out differences in FPG GS between these groups. Maternal FPG was also associated with the T2D GS, which would be expected, as there are loci within the T2D GS which also raise fasting glucose (e.g. GCK, MTNR1B\(^7\)). The ADCY5 locus has also been found to be associated with 2-hour glucose values\(^8\). Thus, the observation of a higher T2D GS in women meeting the fasting or 2-hour WHO 2013 criteria for GDM is not surprising. A GWAS
for 1-hour glucose values was not available at the time of writing, but since we found the T2D GS to be associated with 1-hour glucose values in HAPO, it is likely that this explains the higher T2D GS seen in the women meeting this criterion for diagnosis of GDM, and will contribute to the higher T2D GS seen in women with both a fasting and either 1-hour or 2-hour hyperglycaemia. However, it is important to note that the relationships between the T2D GS and the different glucose categories did not appear to be independent of one another, and again, although women meeting the diagnosis for GDM in one category may not meet the thresholds for GDM in other categories, they are likely to have a degree of fasting and postprandial hyperglycaemia which will contribute to their higher genetic risk for type 2 diabetes compared with women without GDM.

One might expect that women with both fasting and postprandial hyperglycaemia would have the highest genetic risk for type 2 diabetes, but we did not observe this for the T2D GS in women with both a FPG ≥5.1 mmol/L and either a 1-hour glucose ≥10 mmol/L or 2-hour glucose ≥8.5 mmol/L. On the whole, the relationship between GDM and a higher T2D GS was clearest for women with a raised 2-hour glucose or a combination of raised fasting and 1-hour or 2-hour glucose, but studies with greater statistical power will be needed to confirm whether genetic risk of T2D is heterogeneous across the different thresholds of glucose tolerance that are part of the WHO 2013 criteria for GDM.

Previous studies investigating the association between genetic risk scores for glycaemic traits and GDM have provided interesting insights into the biology of GDM. For example, in a study including women from HAPO as well as a Canadian cohort-study (Gen3G), a fasting glucose genetic risk score was strongly associated with FPG in pregnant women, explaining a similar variance in FPG to the non-pregnant population\textsuperscript{45}. Furthermore, genetic risk scores for insulin sensitivity and insulin secretion were associated with these traits in pregnancy, emphasising there to be an important shared genetic component to these both in and outside of pregnancy. Several SNPs at risk loci included in the genetic scores for FPG and type 2 diabetes risk in this study have previously been associated with GDM at genome-wide significance (CDKAL1, G6PC2, GCKR, MTNR1B\textsuperscript{44,45}) and at lesser-degrees of significance (e.g. HNF1A, TCF7L2, HHEX/IDE, PPARG\textsuperscript{35,36,46}). These loci have been implicated in diverse physiological processes influencing glucose metabolism, such as beta cell function and insulin secretion, and insulin resistance secondary to lipodystrophy and disrupted liver lipid metabolism\textsuperscript{46,47}. Along with previous studies showing associations between GDM and genetic risk scores including SNPs at risk loci associated with type 2 diabetes\textsuperscript{43,48}, our study supports the growing evidence that

<table>
<thead>
<tr>
<th>(A) HAPO</th>
<th>Glucose measure</th>
<th>Beta coefficient (mmol/L) per one unit higher FPG GS (95% CI)</th>
<th>Beta coefficient (mmol/L) per one unit higher FPG GS, with adjustment for other glucose values (95% CI)</th>
<th>Beta coefficient (mmol/L) per one unit higher T2D GS (95% CI)</th>
<th>Beta coefficient (mmol/L) per one unit higher T2D GS, with adjustment for other glucose values (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>0.028 (0.023-0.032)**</td>
<td>0.022 (0.018-0.027)**</td>
<td>0.008 (0.004-0.011)**</td>
<td>0.003 (-3.8 x 10^-6)</td>
<td></td>
</tr>
<tr>
<td>1-hr\textsuperscript{c}</td>
<td>0.060 (0.040-0.081)**</td>
<td>0.009 (-0.007-0.025)</td>
<td>0.051 (0.037-0.066)**</td>
<td>0.019 (0.008-0.031)**</td>
<td></td>
</tr>
<tr>
<td>2-hr\textsuperscript{c}</td>
<td>0.032 (0.016-0.048)**</td>
<td>0.0003 (-0.013-0.013)</td>
<td>0.034 (0.022-0.045)**</td>
<td>0.009 (0.00001-0.018)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(B) DIP</th>
<th>Glucose measure</th>
<th>Beta coefficient (mmol/L) per one unit higher FPG GS (95% CI)</th>
<th>Beta coefficient (mmol/L) per one unit higher FPG GS, with adjustment for other glucose values (95% CI)</th>
<th>Beta coefficient (mmol/L) per one unit higher T2D GS (95% CI)</th>
<th>Beta coefficient (mmol/L) per one unit higher T2D GS, with adjustment for other glucose values (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>0.050 (0.039-0.061)**</td>
<td>0.030 (0.021-0.039)**</td>
<td>0.016 (0.008-0.025)**</td>
<td>-0.001 (-0.008-0.006)</td>
<td></td>
</tr>
<tr>
<td>1-hr\textsuperscript{c}</td>
<td>0.136 (0.093-0.179)**</td>
<td>0.034 (-0.35 x 10^-6)-0.067)</td>
<td>0.110 (0.079-0.141)**</td>
<td>0.055 (0.030-0.078)**</td>
<td></td>
</tr>
<tr>
<td>2-hr\textsuperscript{c}</td>
<td>0.071 (0.038-0.105)**</td>
<td>-0.015 (-0.042-0.011)</td>
<td>0.065 (0.041-0.089)**</td>
<td>0.014 (-0.005-0.033)</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; DIP, Atlantic Diabetes in Pregnancy Study; HAPO, Hyperglycemia and Adverse Pregnancy Outcome Study. \textsuperscript{*}These analyses were performed in HAPO as it was a representative sample of pregnant women of European ancestry. \textsuperscript{4}As ATLANTIC-DIP had a case-control design the beta coefficients will not be representative of the general pregnant population but are presented for comparison with HAPO. The 1-hour and 2-hour glucose measures refer to the glucose level measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test. ** P value <0.001, <0.01 after Bonferroni correction. *** P value <0.001, remained <0.001 after Bonferroni correction.
genetic determinants of glycaemic traits influence both of these phenotypes.

Although genetic predisposition will contribute to the underlying pathophysiology of GDM, it explains only part of GDM risk. So far, models including genetic risk scores for glycaemic traits have shown limited predictive ability, suggesting they may not be sufficiently accurate to be used on their own in determining who should be screened for GDM. Therefore, it is still important to consider other well established risk factors, such as parity, maternal age, BMI, ethnicity and socioeconomic background in stratifying risk of GDM.

This work specifically examining the genetic risk of type 2 diabetes in women diagnosed with GDM according to different measures of glucose tolerance supports the results from the recent HAPO Follow-Up Study, which showed that women diagnosed with GDM post-hoc according to WHO 2013 criteria had a higher risk for type 2 diabetes 10 to 14 years after pregnancy. We observed the highest BMIs in women diagnosed with GDM by fasting hyperglycaemia only or both criteria, which is consistent with previous research showing that women diagnosed with GDM by the WHO 2013 criteria were more overweight than those diagnosed by WHO 1996 criteria. However, the associations seen for GDM with FPG GS and T2D GS are not driven by BMI (the genetic variants included within the scores do not primarily affect FPG and T2D risk because of an effect on BMI), suggesting that women with fasting hyperglycaemia in pregnancy are likely to have both BMI-related metabolic factors and a genetic predisposition contributing to type 2 diabetes risk. Furthermore, women with an isolated 2-hour hyperglycaemia did not have a significantly higher BMI than controls, which could suggest a more important role for genetic predisposition in this group of women. However, non-genetic environmental factors related to development of type 2 diabetes such as diet, exercise and socioeconomic deprivation remain a key consideration, as genetics will explain only a portion of risk for type 2 diabetes in women with a history of GDM. For example, a recent study of 2,434 women of white ethnicity found that ~26% women with a history of GDM and a

Figure 3. Plots showing mean fasting plasma glucose (FPG) (A) or type 2 diabetes (T2D) (B) genetic score (GS) in each gestational diabetes (GDM) glucose diagnostic category in the Hyperglycaemia and Adverse Pregnancy Outcome Study (HAPO) and Atlantic Diabetes in Pregnancy Study (DIP). The 1-hour and 2-hour glucose groups refer to glucose levels measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test. The control group include women with a FPG <5.1 mmol/L, 1-hour glucose <10 mmol/L and 2-hour glucose <8.5 mmol/L. The fasting only group includes women with a FPG ≥5.1 mmol/L, a 1-hour glucose <10 mmol/L and 2-hour glucose <8.5 mmol/L. The 1-hour only group includes women with 1-hour glucose ≥10 mmol/L, FPG <5.1 mmol/L and 2-hour glucose <8.5 mmol/L. The 2-hour only group includes women with a 2-hour glucose ≥8.5 mmol/L, FPG <5.1 mmol/L and 1-hour glucose <10 mmol/L. The remaining group includes women with both a FPG ≥5.1 mmol/L and either a 1-hour glucose ≥10 mmol/L or 2-hour glucose ≥8.5 mmol/L, or both. Error bars show 95% confidence intervals. *P value for comparison between cases and controls <0.05 **P value for comparison between cases and controls <0.01. ***P value for comparison between cases and controls <0.001. All P values survived Bonferroni correction at α=0.05 except for the FPG GS in women with 1-hour hyperglycaemia in HAPO and the T2D GS in women with isolated fasting or 1-hour hyperglycaemia in HAPO and DIP.

Wellcome Open Research 2021, 5:175 Last updated: 03 JUN 2021
type 2 diabetes genetic risk score in the highest quartile had developed diabetes at follow-up compared with ~23% of women in the lowest genetic risk score quartile\textsuperscript{16}. The GSs in this study were not analysed for their association with incident T2D in the HAPO Follow-Up Study, but this would be useful to establish and make direct comparisons with the results of this work in the future.

In the longer-term, although using the lower FPG threshold from the WHO 2013 criteria for identifying GDM will result in more cases diagnosed, these women will be an important target for long-term follow-up. It is not known whether lifestyle interventions such as guided diet and exercise programmes could modify risk of progressing to type 2 diabetes in women with a history of GDM and a high genetic risk. A study of 1,744 women suggested that risk of developing type 2 diabetes after a pregnancy affected by GDM was greatest in women with a high genetic risk score and poor diet\textsuperscript{16}. On the other hand, while the Diabetes Prevention Program (DPP)\textsuperscript{99} trial found that lifestyle intervention or metformin treatment reduced risk of progression to type 2 diabetes in women with impaired glucose tolerance and a history of GDM (according to relevant criteria at time of diagnosis), a genetic risk score for type 2 diabetes did not influence treatment response\textsuperscript{11}. Neither of these studies included women specifically diagnosed by WHO 2013 criteria, but it is clear from this work and that of the HAPO Follow-Up Study that these women would benefit from monitoring after pregnancy and should be considered for targeted lifestyle interventions in public health policies focussing on prevention of type 2 diabetes in adults.

There are limitations of this study that are important to consider. The small number of cases of GDM included has been mentioned and this could have meant that the study was underpowered to show clear differences in T2D GS between the different diagnostic categories. We also studied women from two different studies, where there were notable differences in clinical characteristics, even for women without GDM. Additionally, the FPG and T2D GS were consistently higher in DIP than in HAPO. This is likely to reflect differences in SNPs used to generate the genetic scores and possibly a slightly higher genetic disposition to a raised FPG and type 2 diabetes in DIP. Meta-analysis would have improved power, but was not appropriate due to these differing aspects of each study. However, there were remarkably similar patterns for the genetic score associations amongst the different diagnostic groups in both studies. The results of these analyses are therefore likely to be applicable to women of European ancestry, but further larger-scale studies, including analysis of women with diverse ancestry, will be needed to confirm the associations identified in this study.

In conclusion, women diagnosed with GDM according to the newest WHO 2013 criteria, regardless of how the diagnosis is met, have a higher genetic risk for type 2 diabetes compared with women without GDM. Overall, the criteria identify an important group of women at risk for adverse pregnancy outcomes as well as a higher risk for developing future type 2 diabetes\textsuperscript{9}, which can partly be explained by genetic predisposition. In addition, this study has added to the literature confirming genetic predisposition to type 2 diabetes in women with GDM and supports the call for considering GDM as a key area of investigation in the field of genetics-led precision medicine.

**Data availability**

**Underlying data**

Data is not freely available due to it consisting of potentially identifiable information, and as such is held securely to protect the interests of research participants in line with the guidance from the relevant ethics committees. However, the ethics committees will allow data analysed and generated in this study to be available to researchers through open collaboration. For access to the data used in this study please contact Dr Rachel Freathy (r.freathy@exeter.ac.uk) and Professor William Lowe Jr (wlowe@northwestern.edu) in relation to HAPO and Dr Rachel Freathy and Professor Fidelma Dunne (fidelma.dunne@nuigalway.ie) in relation to Atlantic DIP. Requests will be reviewed as soon as possible on receipt and will be facilitated with an agreement to ensure that data is transferred and held securely and results of new analyses shared with the relevant study investigators. The websites describing the studies and other data available are https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000996.v4.p1 for HAPO and http://atlanticdipireland.com/ for Atlantic DIP.

**Extended data**


The file contains an extended data table with sensitivity analyses adjusting the genetic scores for maternal pre-pregnancy BMI and age and a figure with a directed acyclic graph (DAG) showing how the relationships between the genetic scores and GDM diagnostic category are not driven by maternal pre-pregnancy BMI or age.

**Acknowledgements**

We acknowledge the work of the HAPO and DIP original investigators, whose names can be viewed in their original publications. We acknowledge the role of all professionals and families who contributed to HAPO and DIP. We acknowledge the use of the University of Exeter High-Performance Computing (HPC) facility in carrying out this work. Part of this study has been conducted using the UK Biobank Resource under Application 7036.

**Prior publication**

Parts of this work were presented at the European Association for the Study of Diabetes Annual Meeting, Stockholm, Sweden, 14–18 September 2015, the Royal College of Obstetricians and Gynaecologists Annual Academic Meeting, 8–9 February 2018, the East of England Deanery Registrar Prize Meeting, 15 June 2018 and the European Association for the Study of Diabetes Diabetic Pregnancy Study Group Annual Meeting, Graz, Austria, 5–8 September 2019. A previous version of the manuscript was posted as a preprint on bioRxiv, 22 June 2020 (doi: https://doi.org/10.1101/671057).
References


Page 13 of 29
PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Peer Review Status: ✓ ✓ ❓

Version 3

Reviewer Report 19 April 2021

https://doi.org/10.21956/wellcomeopenres.18435.r43239

© 2021 Shaat N. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✓ Nael Shaat
  1 Department of Endocrinology, Skåne University Hospital, Malmö, Sweden
  2 Department of Clinical Sciences, Genomics, Diabetes and Endocrinology, Lund University, Malmö, Sweden

The authors have addressed my comments properly. I do not have more comments.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Gestational diabetes

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 06 April 2021

https://doi.org/10.21956/wellcomeopenres.18435.r43237

© 2021 Kawai V. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✓ Vivian K. Kawai

Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

I have no further comments as the authors have provided satisfactory responses to my previous comments.


**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** risk assessment

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

Version 2

Reviewer Report 08 February 2021

https://doi.org/10.21956/wellcomeopenres.18020.r41368

© 2021 Lamri A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amel Lamri
Department of Medicine, McMaster University, Hamilton, ON, Canada

Hughes et al. derived a fasting plasma glucose (FPG) as well as a type 2 diabetes (T2D) genetic risk scores (GS) in participants from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and Atlantic Diabetes in Pregnancy (DIP) studies. Pregnant women were assigned to gestational diabetes (GDM) cases or control groups based on their 75g oral glucose tolerance test results using WHO's 2013 criteria. Four different subgroups of cases were devised depending on whether participants exceeded the diagnosis threshold for fasting, 1h-, 2h-glucose measures, or a combination of these. The authors show that FPG GS was lower in GDM controls compared to GDM cases. This association was the strongest when comparing women with a FPG $\geq 5.1$ mmol/L only (1-hour glucose $<10$ mmol/L and 2-hour glucose $<8.5$ mmol/L) vs. controls. T2D GS was also lower in GDM controls compared to cases.

I concur with all the comments from my fellow Reviewers (1 and 2) on this 2nd version of the manuscript.

In addition, I have the following comments/suggestions:

- Tables 1 and 2: Please specify the effect/other allele, effect allele frequency, and beta of the proxy SNPs.

- Table 3: describe the mean and SD of the two GSs in controls as well as in each case group.

- All non-significant results in relation to GS and GDM associations (results shown in Figure 3): There seems to be a big issue with the small samples size in each case group and hence, large SEs. Non-significant results (or results that do not pass multiple testing) are likely due to a lack of statistical power. Similarly, I do not agree with statement (P9 - discussion):"the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose $\geq 8.5$ mmol/L alone was expected". The authors could (and should) meta-analyze results from HAPO and DIP to increase their power. Given the differences between the two...
studies, adjustments for age and BMI should be considered to reduce between study heterogeneity.

Other Minor Modifications:
- There is no mention in the methods about how LD was estimated in UK Biobank (data version, samples selection, software)
- Table 4: please remove all the mmol/L within the table to facilitate reading, (units can be mentioned in the table’s headers or in the legend).
- Page 9: under “Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria have a higher T2D GS than controls”, please refer to Figure 3B instead of Figure 2B.
- The fact that all weights of T2D GS SNPs were derived from Voigt et al 2010, and that all weights for all FPG GS SNPs were derived from Dupuis et al. 2010 should be mentioned in the methods section under “Generating a genetic score for FPG and type 2 diabetes” (in addition to legends of table 1 and 2) to avoid any confusion with the last column of Table 2.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Genetics and genomics of complex cardio-metabolic traits

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Mar 2021
Alice Hughes, University of Exeter, Exeter, UK
We would like to thank reviewer 3 for their detailed comments on version 2 of the manuscript. We have addressed their points in turn below:

1. **Tables 1 and 2: Please specify the effect/other allele, effect allele frequency, and beta of the proxy SNPs.**

   We have provided the effect/other alleles, EAF and beta for the proxy SNPs in the Tables 1 and 2 as requested. We used the same beta value for proxy SNPs and have clarified this in the table footnote. Thank you for alerting us to this.

2. **Table 3: describe the mean and SD of the two GSs in controls as well as in each case group.**

   We have provided the mean and SD of the GSs to Table 3 as requested.

3. **All non-significant results in relation to GS and GDM associations (results shown in Figure 3): There seems to be a big issue with the small samples size in each case group and hence, large SEs. Non-significant results (or results that do not pass multiple testing) are likely due to a lack of statistical power. Similarly, I do not agree with statement (P9 - discussion): “the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥8.5 mmol/L alone was expected”. The authors could (and should) meta-analyze results from HAPO and DIP to increase their power. Given the differences between the two studies, adjustments for age and BMI should be considered to reduce between study heterogeneity.**

   We agree with the reviewer’s comment that the wide confidence intervals and non-significant P values after adjustment for multiple testing is likely due to the small sample sizes and resulting low power. We mentioned the small sample size could lead to less distinct associations between the diagnostic categories in the eighth paragraph of the discussion, but have clarified this to include the fact that this could be related to low power. It now reads: “The small number of cases of GDM included has been mentioned and this could have meant that the study was underpowered to show clear differences in T2D GS between the different diagnostic categories”.

   Regarding the comment on it being expected that there was not a higher FPG GS in individuals with a raised 2-hour glucose, we agree that in the context of a small study, that this might represent the sample size, rather than a considerably lower genetic predisposition to raised fasting glucose. However, we do think it remains the case that women who meet the criteria for GDM because of a raised 2-hour glucose alone but not a raised fasting glucose will likely have a lower FPG GS than women who meet the criteria because of fasting hyperglycaemia, and that was supported by the results in both cohorts. We have changed the wording of this to reflect these points to: “Thus, the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥8.5 mmol/L alone was likely because these women did not have fasting hyperglycemia. However, larger sample sizes would be needed to confidently rule out differences in FPG GS between these groups.”

   Meta-analysis of the results from both cohorts would improve power, and we did intend to do this when we set-out to complete this work. However, due to the different structures of the separate studies (in HAPO a random subset were genotyped, whilst DIP genotyped
three women without GDM for every one woman diagnosed with GDM using the clinical criteria at the time of recruitment), different SNPs (proxies were used in the HAPO GS, please see the Methods section for more details), higher GSs in the DIP cohort and different proportions of women in the different diagnostic categories, we felt that meta-analysis would not be combining like-for-like. We do think that the similar patterns of association support the findings in both studies, but for the reasons mentioned we took the decision not to meta-analyse. These reasons are shown in paragraph 8 of the discussion, but we agree that a comment making it clear that these were reasons precluding meta-analysis should be added and have done so in paragraph 8 of the discussion: “Meta-analysis would have improved power, but was not appropriate due to these differing aspects of each study”.

4. There is no mention in the methods about how LD was estimated in UK Biobank (data version, samples selection, software)
   Thank you for pointing this important detail about LD estimates out. We have added to the footnotes of Tables 1 and 2 how LD was calculated.

5. Table 4: please remove all the mmol/L within the table to facilitate reading, (units can be mentioned in the table's headers or in the legend).
   We have edited Table 4 to remove the multiple instances of mmol/L to help make it more readable.

6. Page 9: under “Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria have a higher T2D GS than controls”, please refer to Figure 3B instead of Figure 2B.
   Thank you for pointing out this typo, we have corrected it accordingly.

7. The fact that all weights of T2D GS SNPs were derived from Voigt et al 2010, and that all weights for all FPG GS SNPs were derived from Dupuis et al. 2010 should be mentioned in the methods section under “Generating a genetic score for FPG and type 2 diabetes” (in addition to legends of table 1 and 2) to avoid any confusion with the last column of Table 2.
   Thank you for pointing this out. We have added a sentence to that effect in the Methods section (please see response 2 to reviewer 1 for more details).

**Competing Interests:** We are the authors of the article. We have no other competing interests to disclose.
Authors have investigated whether the fasting, 1-hour and 2-hour glucose thresholds from the WHO 2013 criteria for GDM have different genetic susceptibility to raised fasting glucose and type 2 diabetes in women from 2 cohorts, the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and Atlantic Diabetes in Pregnancy (DIP) studies. For this purpose, they used genetic scores for fasting plasma glucose (FPG GS) and type 2 diabetes (T2D GS). The main findings were that the mean FPG GS and mean T2D GS were higher in women with only a FPG ≥5.1 mmol/L (or combined with 1- or 2-h glucose) than in controls. In addition, mean T2D GS in women with a raised FPG alone or with either a raised 1-hour or 2-hour glucose was higher than controls. Authors concluded that women with a history of GDM have a higher risk of type 2 diabetes in later-life and the risk differs according to how the diagnosis of GDM is met.

The paper is interesting. Many questions have already been raised by the other reviewer.

I have 2 comments:
1. The authors should mention the statistical power of the study.
2. I agree with the other reviewer that the analyses should be adjusted for BMI even if the authors have excluded SNPs associated with BMI.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Gestational diabetes.
expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Mar 2021

Alice Hughes, University of Exeter, Exeter, UK

We would like to thank reviewer 2 for their time in helping to improve the manuscript. We have addressed their two points as follows:

1. **The authors should mention the statistical power of the study.** The expected size of any genetic score difference between the case and control groups was unknown. However, as an indicative power calculation, our sample of N=2,628 HAPO and N=1,084 DIP participants both provided 100% power to detect associations between fasting glucose levels and the fasting glucose GS at alpha=0.002, assuming the GS explains 6% variance in glucose levels, which was estimated in 849 pregnant individuals without diabetes in an external study (Exeter Family Study of Childhood Health (EFSOCH)). We have added this information to the Methods under the subheading “Analysis of associations between FPG GS or T2D GS with glucose levels and GDM.” of the “Statistical analyses” section.

2. **I agree with the other reviewer that the analyses should be adjusted for BMI even if the authors have excluded SNPs associated with BMI.** We have addressed adjustments for BMI in response to point number 3 of reviewer 1.

**Competing Interests:** We are the authors of the article. We have no other competing interests to disclose.

Reviewer Report 12 November 2020

https://doi.org/10.21956/wellcomeopenres.18020.r41234

© 2020 Kawai V. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vivian K. Kawai

Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

I have the following comments for the reviewed manuscript:

1. SNPs for FPG risk score in Table 1 comes from Dupuis et al., 2010 study, which is OK since this is probably the largest GWAS for fasting glucose in individuals of European ancestry.

2. However, table 2 shows that selected T2D variants came from different studies and populations. Effect estimates depend largely on the sample size and the allele frequency of the variant in a population, as well as the impact of a variant in specific population
ancestries. Thus, the authors need to comment how this approach could have affect their results and why they select this approach over using a non-weighted GRS or using only estimates from the largest study in European ancestry regardless of the p-value reported. An alternative approach is to use one of the cohort to define the estimates for each variant and then use this estimates in the second cohort to calculate the GRS.

3. The authors argue that BMI is unlikely to explain the association observed between GDM and the risk scores because the variants included into the GRS has no effect on BMI. They also say that adjusting for BMI has the potential to bias estimates since patients with higher risk scores are likely to developed GDM at lower BMI, which is true. However, confounding is a major problem in genetic studies and with the data shown, we cannot rule out that BMI is a major driven of the results, which undermines the study. A sensitivity analysis including pre-pregnancy BMI and maternal age is recommended as well as a discussion of how including BMI in the analysis may affect the estimates.

4. Although this was not the scope of the study, the authors should add a short comment why the performance of these GRS for T2D in the HAPO and DIP cohort was not studied, particularly when they mentioned that women in HAPO cohort with GDM had higher risk for T2D 10 to 14 years after pregnancy. This is a question that probably every reader would have.

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**Is the study design appropriate and is the work technically sound?**
Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**
Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**
Partly

**Are all the source data underlying the results available to ensure full reproducibility?**
Partly

**Are the conclusions drawn adequately supported by the results?**
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** risk assessment

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
We would like to thank reviewer 1 for reviewing the second version of the manuscript, having already commented on the first version. We have made changes to improve the manuscript based on the new comments and have addressed them below:

1. SNPs for FPG risk score in Table 1 comes from Dupuis et al., 2010 study, which is OK since this is probably the largest GWAS for fasting glucose in individuals of European ancestry. Yes, the SNPs and effect size estimates part of the FPG genetic score come from one study (Dupuis et al.)

2. However, table 2 shows that selected T2D variants came from different studies and populations. Effect estimates depend largely on the sample size and the allele frequency of the variant in a population, as well as the impact of a variant in specific population ancestries. Thus, the authors need to comment how this approach could have affect their results and why they select this approach over using a non-weighted GRS or using only estimates from the largest study in European ancestry regardless of the p-value reported. An alternative approach is to use one of the cohort to define the estimates for each variant and then use this estimates in the second cohort to calculate the GRS.

We did not use effect size estimates from different studies. The effect sizes were all derived from one GWAS (Voight et al., which was the biggest and most recently available study at the time of genotyping). This is shown by the superscript “c” in the “Beta” column. The studies in the last column refer to where the SNP was originally identified. Reviewer 3 picked up on this being unclear and we have taken their advice to include a sentence under “Generating a genetic score for FPG and type 2 diabetes” in the Methods section that reads: “All weights for the FPG GS and T2D GS were taken from Dupuis et al.\(^9\) and Voight et al.\(^{26}\), respectively.

3. The authors argue that BMI is unlikely to explain the association observed between GDM and the risk scores because the variants included into the GRS has no effect on BMI. They also say that adjusting for BMI has the potential to bias estimates since patients with higher risk scores are likely to developed GDM at lower BMI, which is true. However, confounding is a major problem in genetic studies and with the data shown, we cannot rule out that BMI is a major driven of the results, which undermines the study. A sensitivity analysis including pre-pregnancy BMI and maternal age is recommended as well as a discussion of how including BMI in the analysis may affect the estimates.

BMI may confound genetic estimates due to collider bias, as we stated in our previous response. We would not expect the relationships between GS and GDM diagnosis to change according to maternal BMI and age as the SNPs are not causally associated with higher BMI or age. The directed acyclic graph (DAG, found in Extended data file: https://doi.org/10.6084/m9.figshare.14180033) illustrates this.

However, since all reviewers have requested it, we have performed analyses adjusted for maternal pre-pregnancy BMI and age (where available) and present the adjusted GS means
and 95% confidence intervals for each GDM diagnostic criteria and controls in an Extended Data table which can be found at the following link:
https://doi.org/10.6084/m9.figshare.14180033

The estimates and associations are very similar to those shown in the main manuscript (see Figure 3; to aid comparison we have added a column in the Extended data table with the unadjusted values). Since BMI and maternal age were not available in all participants (93% of HAPO participants and 51% of DIP participants), the sample size for the adjusted analyses was smaller and there was a corresponding attenuation of the strength of associations (as shown by wider confidence intervals). However, as can be seen by comparing the adjusted and non-adjusted GSs, the estimates were within the 95% CI of the non-adjusted associations, indicating that they were consistent between the adjusted and non-adjusted analyses. We would prefer not to include this data in the main manuscript for the reasons discussed above and in our previous response, but we have included the sentences “sensitivity analyses adjusted for maternal BMI and age did not materially alter the GS relationships (Extended data Tables 1A and 1B)” and “As with the FPG GS, sensitivity analyses adjusted for maternal BMI and age did not materially affect the associations seen (Extended data Tables 1A and 1B).” in the “Women diagnosed with GDM by fasting glucose criteria have a higher FPG GS” and “Women diagnosed with GDM by fasting, 1-hour and 2-hour criteria have a higher T2D GS than controls” sections of the results, respectively.

4. Although this was not the scope of the study, the authors should add a short comment why the performance of these GRS for T2D in the HAPO and DIP cohort was not studied, particularly when they mentioned that women in HAPO cohort with GDM had higher risk for T2D 10 to 14 years after pregnancy. This is a question that probably every reader would have.

The individuals genotyped in this study do not completely crossover with individuals included in the HAPO Follow-Up Study and since the follow-up time has been short so far, we are unlikely to have the power to study the performance of the T2D score with incident T2D in this cohort, although this is something that would be valuable to do in the future. We agree that a comment on this would be helpful and have added the following sentence to the discussion at the end of the sixth paragraph “The GSs in this study were not analysed for their association with incident T2D in the HAPO Follow-Up Study, but this would be useful to establish and make direct comparisons with the results of this work in the future”.

**Competing Interests:** We are the authors of the article. We have no other competing interests to disclose.
Vivian K. Kawai
Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

The manuscript by Hughes A.E. and collaborators titled: All thresholds of maternal hyperglycaemia for the WHO 2013 criteria for gestational diabetes identify women with a higher genetic risk for type 2 diabetes” test the hypothesis that each diagnosed criteria have different genetic risk using a FPGGS and a T2D GS.

I have the following comments:

1. Please clarify what is the objective of the study and the clinical utility.

2. Previous studies have shown the limited utility GRS for T2 (and likely FPG) in the detection of women at risk for GDM, suggesting that either other genetic factors are the main driver of GDM or environmental exposures. The authors did not provide a convincing explanation in their discussion of the relevance of their findings.

3. Having an increase genetic risk for T2D or fasting hyperglycemia is irrelevant if the authors cannot show what are the clinical implications of this genetic susceptibility. It is known that women with GDM are at higher risk for developing T2D in the future, but the real question is whether a high genetic susceptibility or other clinical factors are the main drivers of this risk in women who already experienced GDM.

4. A major drawback of using GS is that they cannot provide mechanistic insights, so it is unclear how the use of GS for T2D and FPG for GDM can provide any relevant information in GDM.

5. Please provide a more comprehensive explanation for the GS calculation.

6. What is the definition of European ancestry: self-reported white or was based on population stratification analysis.

7. Pre-pregnancy BMI and maternal age are well known risk factors for GDM. I suggest supporting the statement that the association seen between the GS and the different diagnostic criteria are not driven by BMI with data. We cannot assume that variants have the same impact in BMI variability in non-pregnant and pregnant populations.

8. Table 4, please confirm that the outcomes follow normal distribution and provide results for DIP

Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?
No

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** risk assessment

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 13 Oct 2020

**Alice Hughes**, University of Exeter, Exeter, UK

We thank the reviewer for their constructive comments on this work. With the help of these comments we have taken the opportunity to improve the manuscript. We have addressed their comments in turn below and updated the manuscript accordingly (Version 2).

1. Please clarify what is the objective of the study and the clinical utility.

Thank you for prompting us to clarify the message of the paper by stating the objective of the study. The objective of the study was to investigate whether there was a difference in genetic risk for fasting hyperglycaemia and type 2 diabetes according to the different diagnostic thresholds of glucose tolerance as part of the WHO 2013 criteria for gestational diabetes (GDM). We originally stated this in the form of a hypothesis to test in the last paragraph of the introduction, but we have updated the introduction to refocus it as an objective of the study instead (paragraph 4 of the “Introduction” section).

In relation to the clinical utility of the study there are several points to consider. The thresholds for fasting, 1-hour and 2-hour glucose in the WHO 2013 criteria were chosen based on their Obstetric risks (i.e. primary caesarean section, large for gestational age baby, HAPO study reference: [https://doi.org/10.1056/NEJMoa0707943](https://doi.org/10.1056/NEJMoa0707943)). Although it is well known that women with a history of GDM have a higher risk of type 2 diabetes in later-life, it is not known if this differs according to how the diagnosis of GDM is met, and whether this may partly reflect underlying predisposing genetic factors. As expected, we observed a higher
genetic risk for fasting hyperglycaemia in women who had met the fasting plasma glucose criteria (>5.1 mmol/L). We observed a higher genetic risk for type 2 diabetes across all diagnostic categories. Therefore, these criteria identify an important group of women with a genetic risk for type 2 diabetes. This is important for the clinical community to be aware of, since there are many different criteria for GDM used across the world which utilise different criteria (for example, in the United Kingdom the fasting glucose cut-off is 5.6 mmol/L and in Denmark a fasting glucose is not included). Our findings support the findings of the HAPO Follow-Up Study, which showed women diagnosed with GDM according to the WHO 2013 criteria had higher rates of disorders of glucose metabolism 10 years later (Reference: https://doi.org/10.1001/jama.2018.11628). The genetic risk is of particular interest for women who meet the criteria for GDM due to a high 2-hour glucose, as we did not observe a significantly higher BMI in this group of women. Therefore, if they had not been identified as having GDM, these women may not necessarily be considered a high-risk group who would require monitoring and follow-up (e.g. with an annual HbA1c). We have added to the discussion to emphasise the potential implications for long-term follow-up (paragraph 6, “Discussion and conclusion” section).

Of course, it is not known whether preventative lifestyle interventions could modify this genetic risk; we touch on this in the discussion in relation women with a history of GDM in the Diabetes Prevention Program (DPP) trial (Reference: https://dx.doi.org/10.2337%2Fdc13-0700). A recent study suggested that a genetic score for type 2 diabetes was more strongly associated with developing type 2 diabetes in women with a history of GDM and a poor diet (Reference: https://dx.doi.org/10.1136%2Fbmjdrc-2019-000850). But, they also point out that the relationship between the T2D genetic risk score and incident type 2 diabetes was modest. We have added to this area of the discussion to provide a more balanced discussion on the potential implications of a high genetic risk for type 2 diabetes, emphasising the uncertainty of whether the genetic risk could be of benefit in targeting public health interventions in relation to post-GDM care (paragraphs 6 and 7).

2. Previous studies have shown the limited utility GRS for T2 (and likely FPG) in the detection of women at risk for GDM, suggesting that either other genetic factors are the main driver of GDM or environmental exposures. The authors did not provide a convincing explanation in their discussion of the relevance of their findings.

We agree that the genetic risk for fasting hyperglycaemia and type 2 diabetes will only explain a portion of risk for GDM. The genetic risk will not explain risks associated with BMI, maternal age, parity and socioeconomic deprivation. In addition, these genetic scores will not explain the higher risks for GDM seen in women of African and South Asian heritage, for example. Whilst this study did not aim to assess the power of the genetic scores to diagnose or predict GDM, we have added to the discussion taking into account these considerations and referencing studies that have focussed on this as a new paragraph in the discussion (paragraph 5 of “Discussion and conclusion” section).

3. Having an increase genetic risk for T2D or fasting hyperglycemia is irrelevant if the authors cannot show what are the clinical implications of this genetic susceptibility. It is known that women with GDM are at higher risk for developing T2D in the future, but the real question is whether a high genetic susceptibility or other clinical factors are the main drivers of this risk in women who already experienced GDM.
We have partially responded to the clinical implications in response to comment 1 and point to the updated version of the discussion. Similar to comment number 2, we agree that genetic risk is likely to explain only a portion of risk for type 2 diabetes and we have added to the discussion to emphasise the importance of other factors (please see paragraph 6 of the “Discussion and conclusion” section and the response to comment 1 above). However, we also believe that genetic risk for type 2 diabetes and fasting hyperglycaemia are likely to explain part of the relationship between GDM and type 2 diabetes in later-life. We discuss this in more detail in paragraphs 4 and 6 of the “Discussion and conclusion” section.

4. A major drawback of using GS is that they cannot provide mechanistic insights, so it is unclear how the use of GS for T2D and FPG for GDM can provide any relevant information in GDM.

We believe that genetic scores provide important insights into the biology of GDM. For example, the risk loci included in the scores have been implicated in beta cell function, proinsulin secretion and impaired insulin action secondary to unfavourable metabolic patterns of adiposity and liver lipid metabolism (References: https://doi.org/10.1371/journal.pmed.1002654 and https://doi.org/10.1038/s41588-018-0084-1). The relevance of this to GDM was underlined in a recent paper by Powe et al. (Reference: https://doi.org/10.2337/db18-0203), which showed associations between genetic risk scores for fasting glucose, fasting insulin, and insulin secretion and sensitivity with GDM. In particular, they also observed strong associations between a fasting glucose GS and fasting glucose in pregnancy, similar to the associations seen outside of pregnancy, emphasising an important shared genetic predisposition. We did not seek to repeat the biological relevance of these associations demonstrated in this paper in our work, but rather show that there is a higher genetic risk for type 2 diabetes associated with the different measures of glucose tolerance in the WHO 2013 criteria for GDM. However, we agree that a discussion considering the likely underlying biology of genetic scores in relation to type 2 diabetes and GDM will help add to the context of the paper and have included a new paragraph in relation to this in the discussion (paragraph 4).

5. Please provide a more comprehensive explanation for the GS calculation.

We have provided a description of the genetic score (GS) calculation in the Methods section under the heading titled “Generating a genetic score for FPG and type 2 diabetes”. We have also included the formula used in Figure 2. We have added a sentence referring to Tables 1 and 2 which show where the beta (effect size) was obtained for each SNP used in the score to clarify this further.

6. What is the definition of European ancestry: self-reported white or was based on population stratification analysis.

European ancestry was based on self-reported white ethnicity in both HAPO and DIP. We have added this to the Methods section under the heading titled “Study population”.

7. Pre-pregnancy BMI and maternal age are well known risk factors for GDM. I suggest
supporting the statement that the association seen between the GS and the different diagnostic criteria are not driven by BMI with data. We cannot assume that variants have the same impact in BMI variability in non-pregnant and pregnant populations.

The SNPs at the risk loci included in the genetic scores influence glycaemic traits independent of BMI. We did not include SNPs which had their main effect on BMI (e.g. FTO). As BMI is not on the causal pathway between the genetic score and the outcome (GDM diagnostic criterion) it is not necessary to adjust for it in analyses, hence why it is not included in the data presented in this paper. Adjusting for BMI also has the potential to bias estimates due to collider-stratification bias (Reference: https://doi.org/10.1093/hmg/ddw433). For example, we observe a paradoxical negative correlation between the T2D GS and pre-pregnancy BMI in HAPO (Spearman's Rho -0.05, P value 0.01). This is not a true association and comes about because individuals with a higher genetic risk score are more likely to develop type 2 diabetes at a lower BMI than individuals with a lower genetic risk score. However, we agree that there are key differences in GDM risk according to BMI, which we have shown in the comparison of BMI between the different diagnostic criteria in Table 3 summarising the clinical characteristics of the participants in the studies. We have expanded on the importance of the role of BMI contributing to risk of type 2 diabetes and GDM in the discussion (see responses to Comments 1 and 3 and paragraphs 5 ad 6 of the “Discussion and conclusions” section).

8. Table 4, please confirm that the outcomes follow normal distribution and provide results for DIP.

Fasting glucose, 1-hour and 2-hour glucose have a positive skew in both HAPO and DIP (hence their presentation of median with IQR in Table 3). A normal distribution of outcomes is not a pre-requisite for linear regression models (Reference: https://doi.org/10.1017/CBO9780511790942), so we do not think this is of concern for this analysis, but we are happy to supply additional information if the reviewer would like this. We have now included a second part to the table with the associations in DIP (which had a similar pattern of associations to HAPO), but with a cautionary note (footnote b to Table 4) that the beta coefficients seen in a case-control study design will not be applicable to a general pregnant population due to the relative over-representation of cases of GDM. Now we have included these analyses P values for association have been corrected for 24 comparisons and we have updated the Methods section under the heading “Statistical analyses”.

Competing Interests: We have no competing interests to declare.